CANONSBURG (dpa-AFX) - Mylan Inc. (MYL) announced that its subsidiary in South Africa, Mylan (Proprietary) Limited, has launched a comprehensive portfolio of antiretroviral products.
Mylan's South African ARV portfolio initially will consist of 11 first- and second-line adult and pediatric regimens. Included are products such as fixed-dose combinations, single blister 'co-packs,' heat-stable products and novel pediatric formulations that have been approved by the U.S. Food and Drug Administration and the World Health Organization.
Copyright(c) 2013 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2013 AFX News
